Lymphoma

Bio-Path Holdings Reports Full Year 2023 Financial Results

Retrieved on: 
Friday, March 8, 2024

“2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Key Points: 
  • “2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.
  • As of December 31, 2023, the Company had cash of $1.1 million, compared to $10.4 million as of December 31, 2022.
  • Net cash provided by financing activities for the year ended December 31, 2023 was $2.2 million.
  • ET to review these full-year 2023 financial results and to provide a general update on the Company.

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 7, 2024

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • 2023 Full Year and Fourth Quarter Financial Results:
    Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of December 31, 2023, were $218.1 million.
  • Non-GAAP net loss was $38.7 million for the fourth quarter ended December 31, 2023, as compared to a non-GAAP net loss of $24.4 million for the fourth quarter ended December 31, 2022.
  • A reconciliation of GAAP to non-GAAP financial results can be found at the end of this news release.

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

Our grant revenue was $0.3 million for the fourth quarter ended December 31, 2023 and was $0.8 million for the full year 2023.

Key Points: 
  • Our grant revenue was $0.3 million for the fourth quarter ended December 31, 2023 and was $0.8 million for the full year 2023.
  • Our total operating expenses for the fourth quarter ended December 31, 2023 were $9.9 million, including $2.2 million in non-cash stock-based compensation expense.
  • Research and development expenses for the quarter totaled $6.7 million, and general and administrative expenses for the quarter totaled $3.3 million.
  • We believe these funds will be sufficient to fund our operations into the first quarter of 2025.

A.I. Supercomputer Market Projected To Reach $3.3 Billion By 2028 with Significant Growth Expected

Retrieved on: 
Monday, March 4, 2024

A report from MarketsAndMarkets said that the AI supercomputer market is projected to grow from USD $1.2 billion in 2023 and is expected to reach USD $3.3 billion by 2028, growing at a CAGR of 22.0% from 2023 to 2028.

Key Points: 
  • A report from MarketsAndMarkets said that the AI supercomputer market is projected to grow from USD $1.2 billion in 2023 and is expected to reach USD $3.3 billion by 2028, growing at a CAGR of 22.0% from 2023 to 2028.
  • The report said: “The Government segment in the AI supercomputer market for application is expected to hold the largest market size during the forecast period in the AI supercomputer market.
  • Moreover, AI supercomputers are also being used to coordinate disaster relief efforts and provide assistance to victims of disasters.
  • AI supercomputers process vast datasets in real time, providing valuable insights into customer behavior, market trends, and operational efficiency.

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
Friday, February 23, 2024

BOSTON, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today presented data highlighting its expanded access program (EAP) for FDA-approved allogeneic stem cell therapy Omisirge® (omidubicel-onlv) and Phase 1 data for its allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.

Key Points: 
  • The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.
  • “The data presented at Tandem provide further evidence of the potential of Gamida Cell’s nicotinamide (NAM) technology to develop potentially curative therapies by expanding and enhancing cells,” said Ronit Simantov, MD, Chief Medical and Scientific Officer of Gamida Cell.
  • It allowed for institutional variability in conditioning regimens and supportive care, more closely reflecting the real-world environment.
  • Patients were heavily pretreated with a median of six prior lines of therapy including CAR-T cell therapy and hematopoietic stem cell transplant.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 22, 2024

Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.

Key Points: 
  • Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.
  • Enrollment in both trials is ongoing, with topline data expected to be reported in the first half of 2025.
  • Kymera unveiled its first-in-class oral STAT6 degrader, KT-621, at its Immunology R&D Day in January.
  • To access the conference call via phone, please dial +1 (833) 630-2127 or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.

A.I. Processors for Cloud & Data Centers Forecasted to Increase to $38 Billion Dollars By 2026

Retrieved on: 
Wednesday, February 21, 2024

As AI becomes increasingly integrated into various industries, data centers must be equipped with the latest hardware to meet computational requirements.

Key Points: 
  • As AI becomes increasingly integrated into various industries, data centers must be equipped with the latest hardware to meet computational requirements.
  • Data centers underpin the remote management and orchestration of resources, enhancing operational efficiency.
  • Precedence Research continued: “Edge computing, which involves processing data closer to its source, demands decentralized data center infrastructure.
  • Data centers at the edge need to be compact, energy-efficient, and highly responsive to deliver real-time processing capabilities.

BostonGene Announces Publication in Collaboration with National Cancer Institute and National Institute of Allergy and Infectious Diseases in Cancer Cell

Retrieved on: 
Thursday, March 7, 2024

Throughout its progression, FL tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment to promote survival and immune evasion.

Key Points: 
  • Throughout its progression, FL tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment to promote survival and immune evasion.
  • Despite the urgent need, current clinical tools inadequately predict disease behavior, underscoring the necessity for risk stratification methods, particularly for early relapsers.
  • The study, led by researchers at the National Institute of Allergy and Infectious Diseases and National Cancer Institute in collaboration with BostonGene, employed a multi-modal approach to comprehensively examine cell-intrinsic and -extrinsic factors governing disease progression and therapeutic outcomes in FL patients enrolled in a prospective clinical trial.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin’s Lymphoma and Myeloma

Retrieved on: 
Thursday, February 29, 2024

Companies granted Fast Track designation may be eligible for more frequent interactions with the FDA, Accelerated Approval and Priority Review, and Rolling Review of a Biologic License Application (BLA).

Key Points: 
  • Companies granted Fast Track designation may be eligible for more frequent interactions with the FDA, Accelerated Approval and Priority Review, and Rolling Review of a Biologic License Application (BLA).
  • “This designation highlights the promise of Indapta’s highly potent NK cell platform and will further accelerate clinical development of our lead drug candidate, IDP-023, for two of the largest unmet needs in B-cell driven blood cancers, non-Hodgkin’s lymphoma and multiple myeloma,” said Dr. Mark Frohlich, CEO of Indapta.
  • Patients being enrolled now in Indapta’s Phase 1 clinical trial are receiving up to three planned doses of IDP-023 with or without interleukin-2.
  • To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors with increased numbers of g-NK cells, with low donor-to-donor variability.

Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth

Retrieved on: 
Thursday, February 29, 2024

A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .

Key Points: 
  • A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .
  • “With the completion of the Seagen acquisition in 2023, Pfizer has significantly expanded its Oncology organization to amplify its efforts to advance new standards of care and improve outcomes for patients,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • Pfizer’s Oncology portfolio is focused on three core scientific modalities: small molecules, antibody drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics.
  • Please read full Prescribing Information , including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm).